Paloma Partners’s Achillion Pharmaceuticals ACHN Stock Holding History

Paloma Partners’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-65,585	Closed	-$395K	–	2395
2019 Q4	$395K	Buy	65,585 +52,785	+412%	+$306K	0.01%	1564
2019 Q3	$46K	Sell	12,800 -14,630	-53%	-$56.4K	﹤0.01%	1881
2019 Q2	$74K	Buy	+27,430	New	+$81K	﹤0.01%	1646
2018 Q4	–	Sell	-26,400	Closed	-$97K	–	1949
2018 Q3	$97K	Buy	+26,400	New	+$78.7K	﹤0.01%	1453
2018 Q1	–	Sell	-13,865	Closed	-$40K	–	2393
2017 Q4	$40K	Buy	+13,865	New	+$50.4K	﹤0.01%	1825
2017 Q3	–	Sell	-13,200	Closed	-$61K	–	2611
2017 Q2	$61K	Buy	+13,200	New	+$53.1K	﹤0.01%	2104
2015 Q2	–	Sell	-33,051	Closed	-$326K	–	2011
2015 Q1	$326K	Buy	+33,051	New	+$413K	0.01%	929

Paloma Partners's ACHN Position: Q1 2020 in Review

Paloma Partners sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 65,585 shares — an estimated $395K sold.

Paloma Partners first reported a position in ACHN in Q1 2015 and held it in 7 quarters. The position peaked at $395K in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

Paloma Partners reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Paloma Partners sold 65,585 Achillion Pharmaceuticals shares in Q1 2020, an estimated $395K.
Paloma Partners first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 7 quarters.
Paloma Partners's Achillion Pharmaceuticals position peaked at $395K in Q4 2019.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.